	US 12,092,648 B2
	Detection of glucuronidated and 3-bromotyrosine
Stanley L. Hazen, Pepper Pike, OH (US); and Zeneng Wang, Shaker Heights, OH (US)
Assigned to The Cleveland Clinic Foundation, Cleveland, OH (US)
Filed by The Cleveland Clinic Foundation, Cleveland, OH (US)
Filed on Feb. 9, 2022, as Appl. No. 17/668,261.
Application 17/668,261 is a division of application No. 16/281,811, filed on Feb. 21, 2019, granted, now 11,249,091.
Claims priority of provisional application 62/633,693, filed on Feb. 22, 2018.
Prior Publication US 2022/0163540 A1, May 26, 2022
Int. Cl. G01N 33/53 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/6893 (2013.01) [G01N 2800/122 (2013.01); G01N 2800/52 (2013.01)]

8 Claims

1. A system comprising:

a) a urine sample from a subject having, or suspected of having, asthma and/or an eosinophilic disorder; and

b) a de-glucuronidation agent that, when added to said urine sample to generate a composition, liberates 3-bromotyrosine from 4-O-glucuronide-3-bromotyrosine in said urine sample to generate free bromotyrosine, and

c) stable isotope labeled 3-bromotyrosine molecules.